Literature DB >> 19591627

Overview of biologic therapy for Crohn's disease.

Gerald W Dryden1.   

Abstract

Therapy for Crohn's disease (CD) is evolving at breakneck speed. Biologic therapies are assuming ever more important roles in treating this unrelenting, life-long disorder. New evidence suggests that earlier, more aggressive use of biological therapies for CD may improve overall efficacy rates, as well as reduce long-term complications. In addition to optimizing the use of older biologic therapies (antibodies against TNF-alpha), recent and ongoing clinical trials are evaluating the clinical efficacy of a large number of other biologic therapies, honing in on a wide array of immunological targets. The promise of biologic therapies stems from their ability to induce complete and long-lasting remission of symptoms in a way that 'standard' therapies have not been able to accomplish. In this review of biologic therapies for CD, we examine the latest clinical trial data and evidence for mechanism of action of a variety of current and future therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19591627     DOI: 10.1517/14712590903048909

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  11 in total

1.  New insights for pelvic radiation disease treatment: Multipotent stromal cell is a promise mainstay treatment for the restoration of abdominopelvic severe chronic damages induced by radiotherapy.

Authors:  Alain Chapel; Sabine Francois; Luc Douay; Marc Benderitter; Jan Voswinkel
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

Review 2.  Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review.

Authors:  Jan Voswinkel; Sabine Francois; Jean-Marc Simon; Marc Benderitter; Norbert-Claude Gorin; Mohamad Mohty; Loïc Fouillard; Alain Chapel
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

3.  Reversing Ongoing Chronic Intestinal Inflammation and Fibrosis by Sustained Block of IL-12 and IL-23 Using a Vaccine in Mice.

Authors:  Qingdong Guan; Carolyn R Weiss; Shuhe Wang; Gefei Qing; Xi Yang; Richard J Warrington; Charles N Bernstein; Zhikang Peng
Journal:  Inflamm Bowel Dis       Date:  2018-08-16       Impact factor: 5.325

4.  Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism.

Authors:  J M Brown; K Nemeth; N M Kushnir-Sukhov; D D Metcalfe; E Mezey
Journal:  Clin Exp Allergy       Date:  2011-01-24       Impact factor: 5.018

5.  Bone marrow stromal cell transplants prevent experimental enterocolitis and require host CD11b+ splenocytes.

Authors:  Biju Parekkadan; Rabi Upadhyay; Joshua Dunham; Yoshiko Iwamoto; Emiko Mizoguchi; Atsushi Mizoguchi; Ralph Weissleder; Martin L Yarmush
Journal:  Gastroenterology       Date:  2010-10-16       Impact factor: 22.682

6.  Probing predilection to Crohn's disease and Crohn's disease flares: A crowd-sourced bioinformatics approach.

Authors:  Jihad Aljabban; Michael Rohr; Vincent J Borkowski; Mary Nemer; Eli Cohen; Naima Hashi; Hisham Aljabban; Emmanuel Boateng; Saad Syed; Mohammed Mohammed; Ali Mukhtar; Dexter Hadley; Maryam Panahiazar
Journal:  J Pathol Inform       Date:  2022-05-01

Review 7.  Gastro-intestinal autoimmunity: preclinical experiences and successful therapy of fistulizing bowel diseases and gut Graft versus host disease by mesenchymal stromal cells.

Authors:  Jan Voswinkel; Sabine Francois; Norbert-Claude Gorin; Alain Chapel
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

8.  Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease.

Authors:  Thomas Lindebo Holm; Steen Seier Poulsen; Helle Markholst; Stine Reedtz-Runge
Journal:  Int J Inflam       Date:  2012-02-19

9.  Osteonecrosis of the jaw in a Crohn's disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report.

Authors:  Raimund H M Preidl; Tobias Ebker; Martin Raithel; Falk Wehrhan; Friedrich W Neukam; Philipp Stockmann
Journal:  BMC Gastroenterol       Date:  2014-01-08       Impact factor: 3.067

Review 10.  Mesenchymal stem cells as immunomodulators in a vascularized composite allotransplantation.

Authors:  Yur-Ren Kuo; Chien-Chang Chen; Shigeru Goto; Pao-Yuan Lin; Fu-Chan Wei; Chao-Long Chen
Journal:  Clin Dev Immunol       Date:  2012-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.